Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-121 in Severe Hypertriglyceridemia
NCT07657780Phase 1Not yet recruiting
- Sponsor
- CorrectSequence Therapeutics
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of CS-121 in hypertriglyceridemia (5 arms), sponsored by CorrectSequence Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 12 months and Dose-Limiting Toxicities at 14 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CS-121
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT07657780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657780.